

ASX Announcement

Regeneus receives R&D tax incentive refund of \$3.4m

Sydney, Australia – 13 October 2015

Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, today reported that it has received \$3.4m from the Australian Government's Research and Development Tax Incentive Program for activities conducted during the 2015 financial year.

The successful program is designed to encourage local R&D activities and support industry innovation.

Regeneus will use the funds to progress its regenerative medicine product pipeline and anticipates that it will be eligible to receive reimbursement for qualifying expenditure in its R&D programs during the financial year 2016.

Contact for further information:

Investors:

Sandra McIntosh
Company Secretary and investor relations
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au

About Regeneus:

Regeneus Ltd (ASX: RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell-based therapies to address significant unmet medical needs in the human and veterinary health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

The company has two product candidates in Phase I trials: Progenza is an allogeneic "off-the-shelf" adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions and RGS4K is an autologous therapeutic cancer vaccine to treat a wide range of cancer types. The company is developing a stem cell secretions based cream targeting acne and other inflammatory skin conditions. The company has two therapies targeting animal conditions: CryoShot is a clinical-stage allogeneic off-the-shelf adipose stem cell therapy for the treatment of canine and equine osteoarthritis and other musculoskeletal conditions and Kvax is an autologous therapeutic cancer vaccine in clinical trials.